Amgen

EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link:
Amgen Defends Drug Pipeline, Says the Best is Yet to Come
Amgen Defends Drug Pipeline, Says the Best is Yet to Come
TheStreet.com
Amgen
R&D
Flag link:
5 Most Profitable Big Pharma Stocks on the Market Right Now
5 Most Profitable Big Pharma Stocks on the Market Right Now
Motley Fool
Big Pharma
Gilead Sciences
Amgen
Novartis
Biogen
Bristol-Myers Squibb
Flag link:
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Endpoints
Amgen
Novartis
Supreme Court
biosimilars
Neulasta
FDA
Coherus Biosciences
Flag link:
Amgen Sues FDA After Agency Denies Pediatric Exclusivity for SENSIPAR
Amgen Sues FDA After Agency Denies Pediatric Exclusivity for SENSIPAR
FDA Law Blog
Amgen
FDA
pediatric exclusivity
Sensipar
patents
chronic kidney disease
Flag link:
FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson
FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson
Fierce Pharma
FDA
advisory panels
Pfizer
biosimilars
Amgen
Epogen
Procrit
anemia
JNJ
Flag link:
Pfizer's Epogen biosim scores solid backing from FDA staff ahead of panel review
Pfizer's Epogen biosim scores solid backing from FDA staff ahead of panel review
Fierce Pharma
Pfizer
Epogen
biosimilars
FDA
advisory panels
Amgen
anemia
Flag link:
Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug
Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug
Fierce Pharma
Amgen
romosozumab
Radius Health
UCB Pharma
Tymlos
osteoporosis
Flag link:
7 Areas to watch from the ASCO abstracts
7 Areas to watch from the ASCO abstracts
BioPharma Dive
ASCO 2017
oncology
Incyte
Merck
Eli Lilly
CAR-T
NewLink Genetics
Amgen
Roche
Kite Pharma
Juno Therapeutics
Flag link:
Amgen inks first money-back guarantee for Repatha
Amgen inks first money-back guarantee for Repatha
BioPharma Dive
Amgen
Repatha
insurers
Flag link:
With Amgen hot on its heels, Radius races to get a jump on osteoporosis drug rivalry
With Amgen hot on its heels, Radius races to get a jump on osteoporosis drug rivalry
Endpoints
Amgen
Radius Health
osteoporosis
Tymlos
romosozumab
Flag link:
These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016
These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016
Motley Fool
earnings
drug pricing
Biogen
Eli Lilly
AbbVie
Allergan
Merck
Pfizer
Amgen
Flag link:
Three Biotechs Enter…One Biotech Gains
Three Biotechs Enter…One Biotech Gains
Barron's
earnings
Celgene
Alexion
Amgen
Flag link:
Amgen first-quarter profit exceeds Street estimates on lower costs
Amgen first-quarter profit exceeds Street estimates on lower costs
Yahoo/Reuters
Amgen
earnings
Flag link:
U.S. top court grapples over making copycat biologics available sooner
U.S. top court grapples over making copycat biologics available sooner
Yahoo/Reuters
biosimilars
Neupogen
Amgen
Supreme Court
Flag link:
Analysts offer a lukewarm endorsement to Amgen for PhIII migraine data; Arsanis raises $45.5M Series D; Covance faces restructuring
Analysts offer a lukewarm endorsement to Amgen for PhIII migraine data; Arsanis raises $45.5M Series D; Covance faces restructuring
Endpoints
migraines
Amgen
Covance
erenumab
Flag link:
Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?
Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?
Motley Fool
Valeant Pharmaceuticals
Siliq
drug pricing
brodalumab
psoriasis
AstraZeneca
Amgen
Flag link:
Earnings Preview: What To Expect From Amgen On Wednesday
Earnings Preview: What To Expect From Amgen On Wednesday
Forbes
earnings
Amgen
Flag link:
With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
Endpoints
Novartis
Amgen
CGRP blockers
migraines
erenumab
Flag link:
Sanofi Genzyme hit with patent lawsuit over new eczema drug
Sanofi Genzyme hit with patent lawsuit over new eczema drug
Bizjournals.com
Sanofi Genzyme
patents
eczema
Dupixent
Immunex
Amgen
Flag link: